Elitech

IP Roundup

Premium

CapitalBio, Population Genetics Technologies, Illumina, Nanogen, Gen-Probe, BioArray Solutions, Fluidigm

People in the News

Premium

Christian Henry, Howard Birndorf, David Schreiber, Robert Whalen, Stelio Papadopoulos, Heiner Dreismann, Graham Lidgard, David Ludvigson, Nicholas Venuto, John Sweeney, Joan Wilson

The company said in a filing with the US Securities and Exchange Commission that the sale was closed following the completion of an auction process supervised by the court "in which Elitech emerged as the winning bidder."

The transfer to the Pink Sheets was expected after Nanogen received a delisting notice that it did not intend to appeal.

The firm has not paid certain outstanding fees as required for continued listing on the Nasdaq, and it also is in default of a financing agreement with GE.

Nanogen's full-year revenues rose 23 percent, but the firm's cash holdings has fallen to nearly $3 million, which is not enough funding to support its plans for 2009.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.